Barclays analyst Glen Santangelo reinstates coverage on Tarsus Pharmaceuticals (NASDAQ: TARS) with a Overweight rating and a price target of $110.00.

For an analyst ratings summary and ratings history on Tarsus Pharmaceuticals click here. For more ratings news on Tarsus Pharmaceuticals click here.

Shares of Tarsus Pharmaceuticals closed at $78.23 yesterday.